5 patents currently held
13 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Dec 2033. from the record
Of the 13 now held by other companies, 9 were conveyed to Takeda Pharmaceutical Company Limited in the filing they arrived in, and 4 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Dec 2033
Next term end
4
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Dec 2033 · High confidence
Also notable
Ends Jun 2037 · High confidence
Also notable
Ends Aug 2036 · High confidence
Neurotensin Receptor Ligands
US 10,961,199
Cited by 10 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2033.
Conjugate Comprising a Neurotensin Receptor Ligand and Use Thereof
US 10,799,605
The most cited patent in this portfolio, cited by 16 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2037.
Determination of Binding Constants by Means of Equilibrium Shifting
US 10,634,663
The earliest of the three still in force, granted 2020 and renewed since. Its term ends first, in 2036.
Formerly held, still cited
Notable
Ends Feb 2031 · Low confidence
Cited by 10 later US patents, top 25% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
conveyed to Baxter International Inc., Baxter Healthcare S.A. - now held by Takeda Pharmaceutical Company Limited
Also notable
Ends Apr 2031 · High confidence
The most cited patent in this portfolio, cited by 27 later US patents, top 25% of utility patents granted in 2013 in our data. Protection runs to 2031.
now held by Takeda Pharmaceutical Company Limited
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Oct 28, 2027The maintenance fee for Determination of Binding Constants by Means of Equilibrium Shifting (US 10,634,663) comes due Oct 28, 2027. Unpaid by Apr 28, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 19, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Compounds Comprising a Fibroblast Activation Protein Ligand and Use Thereof | 2 in force | to Feb 2043 |
| Conjugate Comprising a Neurotensin Receptor Ligand and Use Thereof | 1 in force | to Jun 2037 |
| Determination of Binding Constants by Means of Equilibrium Shifting | 1 in force | to Aug 2036 |
| Neurotensin Receptor Ligands | 1 in force | to Dec 2033 |
Patents held now
Soonest term end first.
Showing 1 to 5 of 5
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,961,199 | Neurotensin Receptor Ligands In force · High confidence | In force | High confidence | |
| US 10,634,663 | Determination of Binding Constants by Means of Equilibrium Shifting In force · High confidence | In force | High confidence | |
| US 10,799,605 | Conjugate Comprising a Neurotensin Receptor Ligand and Use Thereof In force · High confidence | In force | High confidence | |
| US 12,734,259 | Compounds Comprising a Fibroblast Activation Protein Ligand and Use Thereof In force · High confidence | In force | High confidence | |
| US 12,427,210 | Compounds Comprising a Fibroblast Activation Protein Ligand and Use Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 5: 13 patents in force now held by others · 2 patents ended · 16 applications pending · 7 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.